HomeCompareORTX vs PLD

ORTX vs PLD: Dividend Comparison 2026

ORTX yields 11.98% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.86M in total portfolio value· pulled ahead in Year 4
10 years
ORTX
ORTX
● Live price
11.98%
Share price
$16.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.1K
Annual income
$2,528.78
Full ORTX calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — ORTX vs PLD

📍 PLD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORTXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORTX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORTX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORTX
Annual income on $10K today (after 15% tax)
$1,017.96/yr
After 10yr DRIP, annual income (after tax)
$2,149.46/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,035,966.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORTX + PLD for your $10,000?

ORTX: 50%PLD: 50%
100% PLD50/50100% ORTX
Portfolio after 10yr
$2.98M
Annual income
$2,376,626.98/yr
Blended yield
79.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ORTX
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORTX buys
0
PLD buys
0
No recent congressional trades found for ORTX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORTXPLD
Forward yield11.98%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$44.1K$5.91M
Annual income after 10y$2,528.78$4,750,725.19
Total dividends collected$18.5K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ORTX vs PLD ($10,000, DRIP)

YearORTX PortfolioORTX Income/yrPLD PortfolioPLD Income/yrGap
1$11,898$1,197.60$11,241$540.96+$657.00ORTX
2$14,062$1,331.65$13,019$991.13+$1.0KORTX
3$16,517$1,470.94$15,801$1,870.97+$716.00ORTX
4← crossover$19,288$1,614.74$20,609$3,701.21$1.3KPLD
5$22,401$1,762.27$29,919$7,867.97$7.5KPLD
6$25,882$1,912.75$50,631$18,617.74$24.7KPLD
7$29,759$2,065.39$105,528$51,352.20$75.8KPLD
8$34,061$2,219.43$287,364$174,449.42$253.3KPLD
9$38,820$2,374.13$1,081,760$774,280.77$1.04MPLD
10$44,066$2,528.78$5,908,209$4,750,725.19$5.86MPLD

ORTX vs PLD: Complete Analysis 2026

ORTXStock

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Full ORTX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ORTX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORTX vs SCHDORTX vs JEPIORTX vs OORTX vs KOORTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.